Fannin Partners, LLC
Publicly observedHouston, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Houston | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Fannin Partners, LLC | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | DAHAYJEBV8K1 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant1 Sept 2025Publicly observed
NIH SBIR/STTR award: Developing Scg3 Raptamers as a novel targeted therapy for wet AMD
USD 300,016.00 · National Eye Institute · Source: NIH RePORTER (opens in a new tab)
- Grant1 Apr 2022Publicly observed
NIH SBIR/STTR award: Early clinical development of a novel IL-7R antibody for treating children with relapsed T-cell leukemia
USD 999,997.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.